A Phase Ib, Open-label, Dose Escalation Trial Investigating Different Doses and Schedules of Sym004 in Combination With Platinum-doublets in Subjects With Stage IV Non-small Cell Lung Cancer
Phase of Trial: Phase I
Latest Information Update: 05 Dec 2018
Price : $35 *
At a glance
- Drugs Futuximab (Primary) ; Futuximab/modotuximab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors EMD Serono
- 29 Aug 2016 Status changed from completed to discontinued.
- 09 Nov 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 11 Mar 2015 Planned End Date changed from 1 Aug 2016 to 1 Oct 2015 as reported by ClinicalTrials.gov record.